News from micell technologies A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 23, 2018, 02:16 ET Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this...


Dec 06, 2017, 11:25 ET The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience®

Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint,...


May 16, 2017, 07:08 ET Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

Micell Technologies announced today at the late-breaking trial session of EuroPCR – the official congress of the European Association of Percutaneous ...


Oct 31, 2016, 11:00 ET Positive Five-Year Clinical Data from Micell Technologies' MiStent Presented at TCT 2016

Micell Technologies, Inc. (Micell) today announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I and II trials ...


Oct 13, 2015, 08:00 ET Positive Four-Year Clinical Data from Micell Technologies' MiStent SES Presented at TCT 2015

Micell Technologies, Inc. today announced four-year clinical results from the DESSOLVE I and II trials of its MiStent Sirolimus Eluting Absorbable...


Aug 20, 2015, 08:00 ET Micell Technologies Announces Surgical Technologies Approved as MiStent SES Commercial Manufacturer for CE Mark Countries

Micell Technologies, Inc. announced that its application for a manufacturing partner, Surgical Technologies, Inc. (STI), was approved by British...


May 19, 2015, 08:00 ET EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment

At the late-breaking trials session today at EuroPCR, the official congress of European Association of Percutaneous Cardiovascular Interventions,...


Sep 16, 2014, 08:00 ET Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

Micell Technologies, Inc. today announced that three-year clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus...


Jul 09, 2014, 08:30 ET Micell Technologies Adds to Portfolio of Intellectual Property Protection

Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's...


Oct 28, 2013, 17:41 ET MiStent SES demuestra ser único en el entorno clínico

Micell Technologies, Inc. ha anunciado hoy que los resultados de imagen y clínicos de los ensayos DESSOLVE I y DESSOLVE II de su MiStent Sirolimus...


Oct 28, 2013, 10:03 ET MiStent SES fait la démonstration de ses caractéristiques uniques dans deux études cliniques

Micell Technologies, Inc. a annoncé aujourd'hui que les résultats d'imagerie et cliniques des essais DESSOLVE I et DESSOLVE II de son système...


Oct 28, 2013, 08:00 ET MiStent SES Shown to be Unique in Clinical Setting

Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus...


Oct 28, 2013, 01:08 ET MiStent SES erweist sich im klinischen Umfeld als einzigartig

Micell Technologies, Inc. gab heute bekannt, dass die Bildaufnahmen und klinischen Ergebnisse der Studien DESSOLVE I und DESSOLVE II bezüglich des...


Oct 09, 2013, 02:00 ET Micell Technologies anuncia un acuerdo de desarrollo y distribución para llevar MiStent SES a China

Micell Technologies, Inc. ha llegado a un acuerdo con Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life Science)...


Oct 09, 2013, 02:00 ET Micell Technologies gibt Entwicklungs- und Vertriebsvereinbarung zur Markteinführung von MiStent SES in China bekannt

– Hefei Life Science finanziert und verwaltet klinische Entwicklung und Vertrieb – DURHAM, North Carolina, 9. Oktober 2013 /PRNewswire/ – Micell...


Oct 09, 2013, 02:00 ET Micell Technologies annonce un accord de développement et de distribution dans le but de faire entrer le MiStent SES en Chine

Micell Technologies, Inc. a conclu un accord avec Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life Science) en vue ...


Oct 08, 2013, 02:00 ET Micell Technologies anuncia que se aceptan manuscritos DESSOLVE I

Micell Technologies, Inc. anunció hoy que se ha aceptado para su publicación en la página web JACC Cardiovascular Interventions un artículo de...


Oct 08, 2013, 02:00 ET Micell Technologies annonce l'autorisation de publication du manuscrit DESSOLVE I dans l'American College of Cardiology's Cardiovascular Interventions Journal

Micell Technologies, Inc. a annoncé aujourd'hui qu'un article soumis à un comité, et traitant des résultats d'imagerie et cliniques relatifs à...


Oct 08, 2013, 02:00 ET Micell Technologies gibt die Annahme des Manuskripts über DESSOLVE I für die Veröffentlichung im Fachmagazin American College of Cardiology's Cardiovascular Interventions Journal bekannt

Micell Technologies, Inc. gab heute bekannt, dass der Peer-Review-Aufsatz in dem die Bildgebung und die klinischen Ergebnisse der DESSOLVE...


Oct 01, 2013, 08:00 ET Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China

Micell Technologies, Inc. has entered into an agreement with Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life...


Nov 29, 2010, 07:00 ET Micell Technologies Enrolls First Patient in DESSOLVE I First-In-Human Study of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with...